WASHINGTON (MedPage Today) -- An FDA advisory panel recommended approval for two drugs as add-on therapy for the rare lipid disorder homozygous familial hypercholesterolemia (HoFH), saying the benefits outweigh safety concerns in both instances. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment